Martin Steinbuck

Martin Steinbuck, Ph.D. has worked in a variety of roles in the field of immunology since 2008. From 2008-2009, they were a Research Assistant at The Jackson Laboratory where they investigated the effect of IL21 signaling on Systemic Lupus Erythematosus. From 2009-2010, they were a M.Sc. in Immunology at Imperial College London where they studied the sensitization of cancer cells to TRAIL-induced apoptosis by kinase inhibition. From 2010-2016, they were a PhD Student in Pathology and Immunology at Boston University School of Medicine, where they identified a T-cell receptor-mediated, ligand-independent mode of Notch activation in T-cells. Since 2016, they have worked at Elicio Therapeutics, where they have held the roles of Associate Scientist, Scientist, Senior Scientist, and Associate Director of Research.

Martin Steinbuck, Ph.D. completed their Doctor of Philosophy (PhD) in Immunology at Boston University from 2010 to 2015. Prior to that, they obtained a Master of Science (M.Sc.) in Immunology from Imperial College London from 2008 to 2009. Martin also holds a Bachelor of Science (B.Sc.) in Biomedical Sciences from Kingston University, which they obtained from 2005 to 2008.